Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease
Merck HCV combination achieves 90% cure in advanced cirrhosis
Merck HCV combination effective after failure of first generation of direct-acting antivirals
HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy
Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir
Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR
Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people
Deferring hepatitis C treatment can lead to liver cancer and death, despite cure
Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US
